International Journal of Scientific Research in Modern Science and Technology
ISSN: 2583 -7605 (Online)
© IJSRMST \ Vol. 2 \ Issue 4 \ 2023
Available online at: www.ijsrmst.com

Compartmental and Probabilistic Modelling for Research into the Development of Cancer and its Biological History

John Abhishek Masih[1*], Rajiv Philip[2]

[1]Assistant Professor, Department of Mathematics, St. John's College, Agra, U.P.

[2]Professor, Department of Mathematics, St. John's College, Agra, U.P.

[*]**Email:** jamasih_sjc@stjohnscollegeagra.in

Abstract:

Compartmental models are frequently employed to forecast cancer progression and potential treatment planning. The differential equation governs the cancer model, which is explored along with other mathematical models for cancer such as the exponential, linear, surface, logistic, Gompertz, Mendelsohn, and Bertanffy models. Also, a numerical illustration of the above models has been discussed. The results of the cancer model are beneficial for creating new treatment plans. The Bayes theorem is used in this study's probabilities model to determine the optimum course of treatment for cancer patients. The built-in mathematical model is subjected to a variety of theoretical operations, particularly for the development of new clinical medications. New therapeutic therapies receive specific instruction, and appropriate variables and parameters are also examined. Parallel to this, the model presents crucial construction challenges.

Keywords: Cancer, Medications

1. Introduction:

The second foremost reason of death universal is cancer, closely after cardiovascular illnesses. The World Health Organization's most recent estimate from 2012 states that 8.2 million deaths worldwide, or 15% of all fatalities, were attributed to cancer. Because the prevalence and kinds of cancer vary by region, the worldwide campaign against cancer is hampered. The number of cancer fatalities varies substantially amongst nations of different financial levels. In high- and upper-middle-income countries, population ageing and lifestyle factors like smoking, diet, and physical activity are among the leading causes of cancer deaths, whereas in lower- and middle-income countries, inadequate access to treatments and delayed diagnosis are to blame for a high cancer mortality rate. Low-income nations have a higher prevalence of parasitic and infectious diseases, which accounts for their lower cancer mortality rates. Despite the financing and research in the area, these numbers rise year after year, most likely aided by population expansion and ageing. All of these facts demonstrate how crucial it is to have a community of interdisciplinary scientists and engineers

who are prepared with a wide range of instruments to combat cancer. Wilkie et al. (2017) provided a mathematical model to examine the function of tumor-promoting inflammation for interactions flanked by the invulnerable organisation and cancer, which is now recognised as a mark of cancer (Weinberg 2010). These two outcomes are essentially different groups of outcomes. As a result, the short- and long-term effects of an immune interaction on a tumour may differ; one response dynamic may appear to encourage development in the short term but be better at slowing growth over time, level to the idea of creating potential, while the other permits tumour escape. Several techniques have been used to observe a significant pharmacological treatment impact. Their approach can be used with data on tumour growth. Lively adaptive tumour-induced angiogenesis is a precise model that connects vascular growing through blood current through the jugs. McDougall et al (DATIA).

Figures of significant new goals for relaxing intrusion are highlighted by this original scientific model, which presents an academic and computational scrutiny of the development. The evolving vascular construction and the transport of chemotherapeutic medications to the lump are examined using the DATIA model in order to determine the consequences of altering various corporal and natural model parameters. Numerals of new calming targets for lump control are naked as a result of further simulations of chemotherapeutic therapies under various parameter regimes. It takes a lot of research to develop new treatment modalities and increasethe effectiveness of existing ones. Mathematical models will be a key part of this study as cancer treatment evolves towards customised care, as they may be used to forecast the path of the tumour and improve treatment regimens. Many mathematical models are applied to the study and management of cancer. Models are employed to comprehend the growth and development of cancer. They are used to tailor or even improve existing treatment plans, forecast the success of novel therapies or drug combinations, and provide knowledge on the emergence of treatment resistance. Any mathematical model used to research cancer treatment has a model of tumour growth as its foundation. The normal differential equation (ODE) models of tumour progression are the main topic of this research. Many ODE models have been put up to depict tumour growth and are frequently employed to forecast the effectiveness of cancer treatments. Overall, the findings are relatively ambiguous, with findings indicating that the type of tumour influences the choice of development perfect, at least in portion. As a result, modellers are left without much direction when picking a tumour growth model. The purpose of the study is to investigate the efficacy of Bayes theorem in the diagnosis of diseases states. If a group of patients with known symptoms and a single diagnosis define specified disease, it is possible to calculate the probabilities of particular sets of symptoms, given the specified disease. In the current work, a detailed cancer modeling is used to illustrate several general concepts and directions in mathematical displaying for immune- tumor relations, record of which can be pragmatic to future, better mathematical replicas. On the basis of mathematical methods used in qualitative analysis, parameter acquisition and model calibration are also presented. Finally, founded on the industrialized mathematical perfect, a diversity of therapy methods can be explored and summarized.

This determination deliver valuable info and helpful propositions aimed at the management to better comprehendthe current rank of disease and forecast, stop, and control cancer illnesses; deliver the first- hand direction to backing cancer patients in selecting the most fitting therapy; and indorse preventative events for healthy persons to be free after cancer.

2. Methods

2.1. First Mathematical models

Several of the models discussed in this article were first proposed in first studies of tumour progress, which were focused with developing equations that pronounce the proliferation of cancer cells. By modelling the evolution of the tumour volume, V, over time, the models may forecast the progression of a tumour. The models are explained below, and the model equations utilised in this research are shown in Table 1. The strictures a, b, and c can be changed to better explain a specific set of statistics.

2.2.Exponential:

Cells consistently proliferate, producing two daughter cells each time, during the initial phases of tumour formation. So, the exponential model, in which growth is comparative to inhabitants, provides a suitable account of the early phases of cancer progression. The tumor'sgrowth rate, a, is the proportionality constant. This model seems to be extremely effective in forecasting early development and was frequently used in early analysis of tumour growth curves. It is recognised to fail, yet, at later phases after angiogenesis and nutrition deprivationbegin to show a person.

2.3. Mendelsohn:

Mendelsohn developed an extension of the exponential growth model. According to this concept, population progress is relative to a certain power, b.

Table 1: Mathematical models

S. No.	Models	Governing Equations
1	Linear	$\frac{dV}{dt} = \frac{aV}{V+b}$
2	Logistic	$\frac{dV}{dt} = aV(1 - \frac{V}{b})$
3	Exponential	$\frac{dV}{dt} = aV$

4	Surface	$\frac{dV}{dt} = \frac{aV}{(V+b)^{\frac{1}{3}}}$
5	Gompertz	$\frac{dV}{dt} = aV \ln\left(\frac{b}{V+c}\right)$
6	Mendelsohn	$\frac{dV}{dt} = aV^{b}$
7	Bertalanffy	$\frac{dV}{dt} = aV^{\frac{2}{3}} - bV$

2.4. Logistic:

The logistic equation remained shaped by Pierre Francois Verhulst in 1838. This perfect labels the growth of a populace that is incomplete by a loud volume of b. The logistic reckoning assumes that the growing rate diminutions linearly through size pending it equals zero at the resounding capacity.

2.5. Linear:

The linear model presupposes beginning exponential growing that gradually transforms into constant growth. The initial exponential growth rate in our model formulation is represented by a/b, while the subsequent endless growth rate is represented by a. Early studies used the model to examine the expansion of cancer cell gatherings.

2.6. Surface:

The external model presupposes that just a thin coating of the tumor's surface cells is actively dividing, whereas the cells inside solid tumours are mitotically inert and do not divide. Again,we assume exponential growth in the early stages, with surface growth taking over in the latter stages.

2.7. Bertalanffy:

Ludwig Bertalanffy developed the Bertalanffy equation as a model aimed at creature growth. This model presupposes that tumour volume decreases owing to cell demise and that development occurs proportionately to tumour surface part. This model was proven to be the most accurate in describing the development of human tumours.

2.8. Gompertz:

In instruction to understand human death curves, Benjamin Gompertz developed the Gompertz model in 1825. The perfect is a generalisation of the logistic classical with an asymmetrical sigmoidal curve at the

inflection point. Later, the curve was used to simulate the expansion of complete organisms, and more recently, it was discovered to offer the greatest matches for the growth of breast and lung cancer.

2.9. Chemotherapy

We evaluated the predictions made by the growth models alone as well as how the projections changed when chemotherapy remained included in the mock-ups. This is crucial because growing models are frequently used to forecast how well cancer treatments will work. We pick a straightforward application of chemotherapy since this is only meant to be illustrative. We suppose that the tumour is constantly being affected by medication C0. In order to identify the factors that result in the tumour being eliminated, we simply take the term C0V out of each equation and perform stability analysis once more.

Table 2: Model forecasts in the nonappearance of chemotherapy

S. No.	Model	Maximum Value	Doubling Time	Growth Condition
1	Linear	∞	$\frac{b \ln 2}{a}$	$\frac{a}{b} > 0$
2	Logistic	b	$\frac{\ln 2}{a}$	$a > 0$
3	Exponential	∞	$\frac{\ln 2}{a}$	$a > 0$
4	Surface	∞	$\frac{(b)^{\frac{1}{3}} \ln 2}{a}$	$\frac{a}{(b)^{\frac{1}{3}}} > 0$
5	Gompertz	b – c	$\frac{\ln 2}{a \ln(\frac{b}{c})}$	$a \ln(\frac{b}{c}) > 0$
6	Mendelsohn	∞	$\frac{\ln 2}{a}$	$a > 0$
7	Bertalanffy	$(\frac{a}{b})^3$	$\frac{\ln 2}{a - b}$	$a - b > 0$

Table 3: Model guesses in the attendance of chemotherapy

S. No.	Model	Maximum Value	Minimum concentration needed to cure
1	Linear	$\frac{a}{c_0} - b$	$c_0 = \frac{a}{b}$
2	Logistic	$\frac{b(a - c_0)}{a}$	$c_0 = a$

3	Exponential	∞	$c_0 = a$
4	Surface	$\frac{(a)^3}{c_0} - b$	$c_0 = \frac{a}{(b)^{\frac{1}{3}}}$
5	Gompertz	$\frac{b}{e^{\frac{c_0}{a}}} - c$	$c_0 = a \ln(\frac{b}{c})$
6	Mendelsohn	$(\frac{c_0}{a})^{\frac{1}{b-1}}$	$c_0 = a$
7	Bertalanffy	$(\frac{a}{b + c_0})^3$	$c_0 = a - b$

3. Graphical Analysis on All Models

Table 4: Numerical Values or parameters

S. No.	Model	Value of a	Value of b	Value of c	SSR	AICc
1	Linear	58.7 mm^3/d	1690	---	**41200**	**74.8**
2	Logistic	0.037 /d	2000 mm^3	---	**39800**	**74.5**
3	Exponential	0.0262 /d	---	---	**54900**	**69.8**
4	Surface	0.265 mm/d	506 mm^3	---	**44000**	**75.2**
5	Gompertz	0.279 /d	139200 mm^3	12000 mm^3	**40100**	**88.6**
6	Mendelsohn	0.286 /d	0.616	---	**35100**	**73.6**
7	Bertalanffy	0.306 mm/d	0.119 /d	---	**33700**	**73.3**

Figure 1: Growth Rate of Cancer

3.1 Second Statistical model



Figure 2: Bayesian network modeling for medical diagnostic problem

3.2. Probabilistic formulation:

We are formulating a problem of maximization. We suppose that $D_1, D_2, \ldots\ldots\ldots\ldots D_n$ stay the n diseases beneath thought and let S1, $S_2, \ldots\ldots\ldots S_m$ be the m conceivable symptoms.

(a) Let Likelihoods $P(D_1)$, $P(D_2)$, ……., $P(D_n)$ where $P(D_j)$ is the likelihood that patient agonizes after the j-th disease. It may be obtained by discovery the section of individuals in the zone who have ached from the sicknesses in the preceding years.

(b) Let Likelihoods $P(S_i|D_j) = p_{ij}$ $(i = 1, 2, \ldots\ldots,n; j = 1, 2, \ldots\ldots,m)$, where p_{ij} is the likelihood that a being suffering after the disease D_j demonstrations the symptoms S_i.

(c) The set of symptoms

$$A = S_{i1} \cap S_{i2} \cap S_{i3} \ldots\ldots\ldots \cap S_{ip} \cap S_{k1} \cap S_{k2} \cap \qquad \cap S_{kp}, \qquad (1)$$

where $p + q = m$. this implies that the patient shows p indications and fixes not demonstration q symptoms. We assume that (a) the indications are independent, and (b) the illnesses are equally exclusive. In other words, we can show the second set of likelihoods p_{ij}

$$\begin{array}{c} \ldots\ldots \\ S_1 \\ S_2 \\ \vdots \\ S_i \\ \vdots \\ S_m \end{array} \begin{array}{c} \begin{array}{cccccc} D_1 & D_1 & \ldots\ldots & Dj & .. & Dn \end{array} \\ \begin{bmatrix} p_{11} & p_{12} & .. & p_{1j} & .. & p_{1n} \\ p_{21} & p_{22} & .. & p_{2j} & .. & p_{2n} \\ \vdots & \vdots & & \vdots & & \vdots \\ p_{i1} & p_{i2} & & p_{ij} & & p_{in} \\ \vdots & \vdots & & \vdots & & \vdots \\ p_{m1} & p_{m2} & & p_{mj} & & p_{mn} \end{bmatrix} \end{array} \qquad 2$$

We have to get $P(D_j|A)$ for $j = 1, 2, \ldots\ldots,m$. we have to get the likelihoods for the many disease haughty that the patient is display the set of indications A for this we use the theorem of compound probability which is of the form

$$P(D_j) = P(A) = P(A)\,P(A|\,D_j) \quad 3$$

So that,

$$P(D_j \mid A) = \frac{P(D_j)P(A \mid D_j)}{P(A)} \quad 4$$

Here, we are using the theorem of compound probability and the independence of thesymptoms, we obtained

$$P(A \mid D_j) = p_{i_1 j} p_{i_2 j} \ldots . p_{i_p j} (1 - p_{k_1 j}) \ldots . (1 - p_{k_q j}). \quad 5$$

The indications *A* can appear owing to some of the illnesses D_1 *or* D_2*…….or Dm*, and these illnesses are assumed to be mutually select so that, using the theorem of total probability, we obtain

$$P(A) = P(A \cap D_1) + P(A \cap D_2) + \ldots\ldots\ldots + P(A \cap D_n) = \sum_{j=1}^{n} P(A \cap D_j) \quad 6$$

From (4) and (6),

$$P(D_j \mid A) = \frac{P(D_j)P(A \mid D_j)}{\sum_{j=1}^{n} P(D_j)P(A \mid D_j)} \quad 7$$

The equation (7) is known as Baye's formula. Using the known values of $P(D_j)$ and p_{ij} as also (5) and (7), we can find $P(D_j|A)$ for $j = 1, 2, \ldots\ldots, m$. The value of j for which this probability is maximum gives the most likely diseases from which the person showing the setof symptoms *A* may be suffering.

4. Numerical Example:

In a Laboratory, the collected samples were tested for cancer, where blood cancer test performed.

a) 25% of the patients at the clinical have cancer.

b) Among those who have cancer 90% test positive on blood cancer test.

c) Among those who have not cancer, 3% test positive on the blood cancer test.

Calculate the probability that a patient has the cancer, if the blood cancer test is positive.

There are three possible events for the experiment.

i. X = has the cancer that is test positive,

ii. Y = dose not have the cancer that is test negative,

iii. Z = cancer blood test positive.

Given that $P(X) = \frac{25}{100} = 0.25$

In this situation, $P(\mathrm{X})$ is the total likelihood of diseased patient that is 0.25. Therefore,

$$P(Y) = 1 - P(\mathrm{X}) = 1 - 0.25 = 0.75$$

Since $P(Y)$ is the total likelihood of non – diseased patients that is 0.75.

So, $P(Z)$ is the unqualified likelihood of cancer blood test for positive cases. The goal is to measure $P(\mathrm{X}|Z)$ that the probability of cancer cases given that the patient has a positive test (Z).

So, $P(Z|X) = \frac{90}{100} = 0.90,$

$$P(Z|Y) = \frac{3}{100} = 0.03$$

Therefore, by using Bayes theorem, the system find $P(\mathrm{X}|Z)$. By definition,

$$P(X|Z) = \frac{P(Z|X).P(X)}{P(Z|X)P(X) + P(Z|Y)P(Y)}$$

$$P(X|Z) = \frac{0.9 * 0.25}{0.9 * 0.25 + 0.03 * 0.75}$$

$$P(X|Z) = 0.90909090 = 0.91 \; or \; 91\%$$

5. Conclusions

According to our findings, the typical that best matches experimental statistics may not also be the archetypal that best expects future progress, with predicted outcomes changing by as much as a factor of 12 depending on the tumour growth model used. We anticipate that the results given here determination encourage additional research into the impact of cancer development model selection on anticipated treatment results and that academics determination take into account factors other than greatest fit when choosing a growing model. This study put forth a number of broad guidelines for creating mathematical models of immune-tumor interactions. The modelling of pancreatic cancer forecast when receipt immunotherapy showed the value of these ideas. When a model was created following these philosophies, and the study of the perfect was utilised to give helpful pointers for developing novel therapeutic therapies, it was further evidence that these ideas were beneficial. The sensitivity of the system factors are analysed, and recommendations for new treatments are also given. Furthermore mentioned were the new modelling techniques' shortcomings and difficulties. The development of these modelling tools to meet specific demands will be part of future effort. A doctor (physician) diagnoses a disease by observing the symptoms. Patients suffering from different diseases may show the same symptoms, but the probabilities of different diseases vary, and the physician usually diagnoses

the diseases as the one with the largest probability. Therefore, it will be helpful to separate the diseases with their probabilities on the basis of symptoms.

References:

1. Fry, B., 2009. A mathematical model of diffusion-driven tumor growth with viral therapy.
2. Ghosh, D., Khajanchi, S., Mangiarotti, S., Denis, F., Dana, S.K. and Letellier, C., 2017. How tumor growth can be influenced by delayed interactions between cancer cells and the microenvironment?. *BioSystems*, *158*, pp.17-30.
3. Peirce S M. "Computational and Mathematical Modeling of Angiogenesis". Microcirculation (2008). 15(8). pp.739–751.
4. Xu, J., Vilanova, G. and Gomez, H., 2016. A mathematical model coupling tumor growth and angiogenesis. PloS one, 11(2), p.e0149422.
5. Mahardika, R., & Sumanto, Y. D. (2019, May). Routh-hurwitz criterion and bifurcation method for stability analysis of tuberculosis transmission model. In *Journal of Physics: Conference Series* (Vol. 1217, No. 1, p. 012056). IOP Publishing.
6. Ucar, E., Özdemir, N., & Altun, E. (2019). Fractional order model of immune cells influenced by cancer cells. *Mathematical Modelling of Natural Phenomena*, *14*(3), 308.
7. Vaghi, C., Rodallec, A., Fanciullino, R., Ciccolini, J., Mochel, J. P., Mastri, M., ... & Benzekry, S. (2020). Population modeling of tumor growth curves and the reduced Gompertz model improve prediction of the age of experimental tumors. *PLoS computational biology*, *16*(2), e1007178.

Cite this Article:

John Abhishek Masih, Rajiv Philip" ***Compartmental and Probabilistic Modelling for Research into the Development of Cancerand its Biological History****", International Journal of Scientific Research in Modern Science and Technology (IJSRMST),* ***ISSN:*** *2583-7605* ***(Online)****, Volume 2, Issue4, pp. 01-10, April 2023.*

Journal URL: *https://ijsrmst.com/*